on! Finally Gains Pouch Share and Volumes Hold, But Operations Produced Half the Growth and MO Gives Back the Re-Rating

First quarterly report under Salvatore Mancuso as Chief Executive Officer and Heather Newman as Chief Financial Officer, both effective May 14, 2026.

Results vs. Consensus

Q2 2026 Scorecard

Consensus for revenue is compiled on the revenues-net-of-excise-taxes basis, which is how the sell-side models Altria. The $6,111 million net-revenues line is the excise-inclusive figure disclosed alongside it and is not the consensus basis. Coverage that compared the excise-inclusive line against the net-of-excise consensus on the morning of the print produced a revenue beat of roughly 14% that does not exist; the top line was in line to within two-tenths of a point either way.

Year-Over-Year Comparisons

Altria reports cash flows on a six-month basis only. The quarterly operating cash flow and capital expenditure figures above are the first-half statement less the first-quarter statement, both taken from the respective Forms 10-Q. Every income-statement line traces to the earnings-release schedules, which present amortization of intangibles and general corporate expenses below operating companies income; the Form 10-Q folds them into a single caption and reconciles to the same $3,136 million of operating income.

Quarter-Over-Quarter Comparisons

Q2 is a seasonally heavier revenue quarter than Q1 and a seasonally lighter cash quarter, because the state-settlement payment accrued through the prior year is discharged in April. The sequential revenue and volume jumps are calendar, not momentum. The lines to read across are net price realization, the two margin lines and the three share lines, all of which are comparable quarter to quarter, and all of which moved in the same direction except the pouch measures.

Quality of Beat/Miss

• Revenue: Thinner than the headline growth suggests. Revenues net of excise taxes rose 1.2%, but the smokeable revenue bridge shows $309 million of price offset by $279 million of volume and cigarette mix, a ratio of 1.1 to 1 against 1.7 to 1 in the first quarter. Oral tobacco revenues net of excise fell 5.2%. Excise taxes fell 7.0%, helped by the same duty refunds that helped operating income, which flatters the net-of-excise line that consensus is measured against.
• Margins: Divergent by segment and flat in aggregate. Smokeable adjusted operating margin expanded 30 basis points to 64.8%; oral contracted 200 basis points to 66.7%. Consolidated adjusted operating companies income was $3,401 million against $3,354 million, up 1.4% on revenues net of excise up 1.2%, so the total adjusted margin was 63.5% against 63.4%. Reported gross margin fell 146 basis points as cost of sales rose 6.7% against a flat top line.
• EPS: Half of it is not operations. The $0.02 of operating contribution is the smallest in the covered window, against $0.07 in the first quarter. Below-the-line items did the rest, and both are finite: the buyback is running against an authorization that expires in December, and the adjusted tax rate is already at 23.0%.
• Cash: The one clear positive, and largely not operational either. Second-quarter free cash flow of $662 million against $173 million reflects a $0.3 billion smaller state-settlement payment, $2.6 billion against $2.9 billion. First-half free cash flow of $2,893 million grew 1.3%, which is the honest run-rate read.

Revenue. Net revenues of $6,111 million were flat and revenues net of excise taxes grew 1.2% to $5,356 million, essentially where the Street sat. The composition is where the quarter turned. Smokeable net revenues rose 0.7%, with pricing worth $309 million against $279 million of volume and cigarette mix. In the first quarter the same two lines were $330 million and $196 million. Price barely decelerated; the mix charge grew 42%. Oral tobacco net revenues fell 5.3%, with $74 million of lower volume against $31 million of pricing, on a prior-year quarter management described as inflated by promotional timing and a competitor's supply disruption. The all-other category turned positive at $6 million against negative $8 million, a line whose prior-year figure carried acquisition-related items.

Margins. The consolidated picture has not changed since the first quarter: whatever the smokeable segment gains, the oral segment gives back. Total adjusted operating companies income of $3,401 million rose 1.4% and the total adjusted margin was 63.5% against 63.4%, effectively unchanged for a second consecutive quarter. Underneath, smokeable adjusted margin expanded 30 basis points on pricing and duty refunds, while oral adjusted margin fell 200 basis points on lower volume and on trial spending behind the on! PLUS expansion. Reported margins carry a wider gap this quarter because $88 million of asset impairment, exit and implementation costs, $79 million of it in the oral segment, ran through the reported line. Oral reported operating margin was 55.2% against an adjusted 66.7%, an 1,150 basis point spread that will recur while the manufacturing consolidation runs.

EPS. Adjusted diluted EPS of $1.48 grew 2.8%, against 7.3% in the first quarter and 4.4% for full-year 2025. Reported diluted EPS fell 2.8% to $1.37 as the net special-items charge grew from $55 million, or $0.03, in the prior-year quarter to $182 million, or $0.11, driven by the manufacturing consolidation, higher litigation provisions and a dilution loss on the ABI stake. The adjusted number is the working figure, and the composition is the problem: $0.02 of the $0.04 increase is share count and tax rate. Adjusted net earnings grew 1.9% while adjusted EPS grew 2.8%, and the 90 basis point gap is the buyback. That buyback fell to $55 million in the quarter from $280 million in the first, so the mechanism that produced a quarter of the earnings growth is being throttled at the same time.

Segment Performance

Altria does not publish a consolidated adjusted operating companies income figure. The total row is the sum of the three segment lines: $3,018 million, $460 million and negative $77 million. The prior-year comparative of $3,354 million comprises $2,947 million, $500 million and negative $93 million, the last being a reported loss of $108 million less $15 million of acquisition-related items. The same total can be reached top-down from the reported $3,246 million by adding back $88 million of asset impairment, exit and implementation costs and $67 million of litigation charges recorded inside operating companies income.

Smokeable Products

This is the segment carrying the company, and this quarter it carried less. Adjusted operating companies income of $3,018 million grew 2.4% and the adjusted margin expanded 30 basis points to 64.8%, against 6.3% growth and 70 basis points of expansion in the first quarter. Revenues net of excise taxes rose 2.0%. Reported operating income grew only 0.4% because litigation provisions were $63 million heavier than the prior year.

The volume line continued to behave better than the decade's pattern. Reported domestic cigarette shipments fell 3.2%, and adjusted for trade inventory movements management put its own decline at 4.5% against an industry 5%. That is the fourth consecutive quarter of moderated industry declines, and it is the second consecutive quarter in which Altria's inventory-adjusted decline was inside the 4% to 5% band we said we would need to see repeated.

"When adjusted for trade inventory movements, domestic cigarette volumes in the second quarter and the first half declined by an estimated 4.5% and 4%, respectively. At the industry level, when adjusted for the same factor, we estimate that domestic cigarette volumes declined by 5% in both the second quarter and in the first half, marking the fourth consecutive quarter of moderated cigarette industry declines." — Heather Newman, Chief Financial Officer

The composition of the share picture has hardened in exactly the way the first quarter warned it might. PM USA gained 30 basis points of total category share while Marlboro lost 150 basis points, its worst year-over-year share erosion in the covered window. Discount volume rose 67.3% and discount now represents 9.6% of the segment's domestic cigarette sticks against 5.5% a year ago, a 403 basis point mix shift in twelve months. The industry's discount segment reached 33.8%, up another 50 basis points sequentially and the same increment the first quarter posted, so the trade-down that produced the share gain is still widening at an undiminished pace rather than flattening. Management's own bridge prices the consequence: volume and cigarette mix cost the segment $221 million of operating income this quarter against $160 million in the first, and $381 million across the half.

Two offsetting items inside the segment matter for how the growth should be read. Refunds of taxes and duties on imported cigarettes were $27 million higher than the prior year, against $51 million higher in the first quarter, and contributed 38% of the segment's entire $71 million adjusted operating income increase. Higher manufacturing and other costs took $44 million. Excluding the refund increment, smokeable adjusted operating income grew 1.5%.

Assessment: The volume moderation is now a two-quarter fact rather than a one-quarter datapoint, and Altria is genuinely outperforming the industry on an inventory-adjusted basis while taking category share. That is the strongest part of the equity case and it survived this quarter intact. What did not survive is the idea that the moderation translates cleanly into profit growth. Net price realization fell from 6.3% to 4.5% because the mix has shifted toward a segment that carries a fraction of premium economics, and the mix charge against operating income is growing faster than the price benefit. Holding 45.5% of a category by adding discount sticks at 67% growth is a defensible commercial strategy and a deteriorating profit pool.

Oral Tobacco Products

The oral segment produced the quarter's genuine surprise and its worst financial line at the same time. On share, the franchise stopped losing: on!'s share of the nicotine pouch category rose 1.0 point sequentially to 14.4%, the first sequential gain since the on! PLUS launch, and its share of the total oral category rose 0.3 points year over year to 8.6%, the first year-over-year gain in the covered window. Total segment retail share was 29.0%, unchanged sequentially. On profit, the segment went backwards: adjusted operating companies income fell 8.0% to $460 million and the adjusted margin fell 200 basis points to 66.7%. Reported operating income fell 23.5% on $79 million of manufacturing-consolidation charges.

"In the second quarter, on! retail share reached 8.6%, up 0.8 share points sequentially and 0.3 share points year-over-year, driven by the introduction of on! PLUS. Early data suggests on! PLUS is resonating with both loyal on! and competitive nicotine pouch consumers, driving incremental volume and share contributions for the brand." — Salvatore Mancuso, Chief Executive Officer

The two memo lines are internally consistent and worth reading together: on! holds 8.6% of total oral tobacco and pouches are 59.9% of total oral tobacco, which puts on! at 14.4% of pouches. Both the numerator and the denominator moved in Altria's favour this quarter for the first time. The year-over-year comparison is still negative, at 1.7 points of pouch-category share lost, but the rate of loss has more than halved from the 4.2 points reported in the first quarter, and the sequential direction has reversed.

The profit line went the other way, for three separable reasons. Reported shipment volume fell 8.5% against an inventory-adjusted 2%, so most of the volume decline is trade inventory unwinding after the first quarter's national pipeline fill. Management attributed the residual to a prior-year comparison inflated by promotional activity taken while a competitor had supply problems. And the segment absorbed introductory trial offers behind the on! PLUS expansion beyond the initial launch markets. None of those is structural on its own. The structural item is the one nobody discussed: pouches carry lower unit economics than moist smokeless, pouches are now 59.9% of the category, and Copenhagen and Skoal shipped 10.9% and 13.7% fewer cans while losing 2.8 and 1.0 points of share.

"Segment performance was impacted by a difficult prior year comparison when 2025 volumes benefited from promotional timing and competitor supply disruptions. Additionally, financial results were impacted by strategic investments behind on! PLUS introductory trial offers as we expanded beyond the initial launch dates." — Heather Newman, Chief Financial Officer

Assessment: This is the first quarter in which the oral franchise's share problem and its profit problem pointed in opposite directions, and that is progress. The share inflection is real, it is corroborated by both the numerator and the denominator, and it arrived faster than the first quarter's data implied it would. But the segment is now shrinking in dollars while gaining in pouches, which is the arithmetic of a mix migration into a structurally thinner category. Altria is winning a growing share of a business that is worth less per can than the one it is losing, and Copenhagen, the profit engine, is still bleeding 2.8 points of share a year. The pouch fix improves the terminal-value case; it does not improve the near-term earnings case, and it will not until pouch volume is large enough to carry the segment on its own.

All Other

The all-other category reported an operating loss of $77 million against $108 million, or $77 million against $93 million on an adjusted basis, so the investment drag narrowed by $16 million. Net revenues were $6 million against negative $8 million, a prior-year figure that carried acquisition-related items. The category now contains NJOY, the Horizon heated-tobacco joint venture, Helix International and new-platform research spending, following the first-quarter decision to stop reporting e-vapor as a separate segment.

Assessment: A narrowing loss in a category with no product in its largest market is cost discipline, not progress. The line will only become interesting when NJOY ACE returns, and the guidance still assumes it does not do so in 2026. The one substantive change this quarter is that the patent obstacle has cleared, which moves the question from whether Altria can re-enter to when it chooses to.

Key Topics & Management Commentary

Overall Management Tone: Steady and noticeably less quantitative than the outgoing team's final call. The first quarter's habit of volunteering the arithmetic behind a result was replaced by qualitative framing, and where a number was requested it was usually supplied as a direction rather than a figure. Pushback was concentrated on two things, why the duty-drawback benefit failed to step up and why price realization decelerated, and both answers were framed as timing and mix rather than as a change in the underlying trajectory. The new chief executive was most specific on the pouch portfolio and least specific on capital allocation, which went unaddressed in prepared remarks for the first time in the covered window.

1. The Volume Moderation Held for a Second Quarter

The claim that carried the stock to an eight-year high in April was that cross-category movement from cigarettes into illicit flavoured disposable vapes has begun to saturate and that enforcement is compounding the effect. This quarter tested it, and it held. Inventory-adjusted domestic cigarette volume fell 4.5% against an industry 5%, the fourth consecutive quarter of moderated industry declines, and Altria outperformed the category for a second straight quarter. Management put the adult vaper population at approximately 20 million at the end of June, essentially unchanged year over year, with the disposable subset down modestly, the same corroborating datapoint offered in April and now with a second reading.

"We believe increased enforcement activity, including supply-related disruptions at the border is helping slow demand for illicit products. While illicit-flavored disposable products remain prevalent, signs of moderating growth continued in the second quarter, and we're beginning to see this reflected in the consumer data." — Salvatore Mancuso, Chief Executive Officer

Management also named the specific enforcement actions for the first time: more than $250 million of federal seizures during the quarter, a state attorney general lawsuit against a leading illicit e-vapor manufacturer, and restrictions imposed by major commerce and payment platforms. That is a more concrete evidentiary base than the April call offered.

Assessment: Two consecutive quarters inside the 4% to 5% inventory-adjusted band, with the industry at 5% both times, is the single most important thing that happened in this quarter and it is being obscured by the share price. Our April note said we would want two more quarters at that rate before treating it as the new baseline. This is the first of the two, delivered with a broader evidence base than the last. The remaining question is unchanged: saturation is arithmetic and should persist, while enforcement is a policy variable, and management still declines to separate their contributions.

2. The Duty Drawback That Did Not Step Up

The one explicit, checkable commitment management made on the April call was that the refund of duties and taxes on imported cigarettes would build as the year progressed. Export volume did build, rising 20.7% sequentially to 736 million contract-manufactured sticks and 54.9% year over year. The refund did not follow. The year-over-year increment fell to $27 million from $51 million in the first quarter, and the chief financial officer confirmed on the call that the absolute benefit was flat sequentially on timing.

"And while refunds of taxes and duties paid on imported cigarettes for the quarter were flat sequentially due to timing factors, we continue to expect export volume and related tax refunds to be higher in the second half of the year with a more balanced benefit across the third and fourth quarters." — Heather Newman, Chief Financial Officer

The company has never sized the absolute benefit. Only the year-over-year increment appears, and only in the Form 10-Q: $51 million in the first quarter, $27 million in the second, $78 million across the half. Because the prior-year first quarter had no export volume at all, the first-quarter increment approximates the first-quarter absolute, which means a flat sequential quarter implies roughly $51 million again and a prior-year second-quarter base near $24 million. That is our estimate, not a disclosure. What is disclosed is that $27 million of a $71 million segment operating income increase came from this item, or 38%, a higher proportion of a smaller number than the first quarter's 32% of $158 million. Strip it and smokeable adjusted operating income grew 1.5%.

Assessment: Management asked to be judged on this and the answer for one quarter is that the ramp did not happen. The explanation offered, the lag between claiming the credit and staging the product, is mechanically plausible and does not imply the benefit is impaired. But the full-year guide explicitly leans on a larger second-half benefit now split evenly across two quarters, and the company has just demonstrated that export volume growing does not guarantee the refund following in the same period. This is the single largest execution risk to the guidance floor, and it is a risk that did not exist in the April framing.

3. Price Realization Decelerates to 4.5%

Smokeable net price realization was 4.5% against 6.3% in the first quarter, a 180 basis point deceleration in one quarter. Management was pressed on it directly and attributed the entire gap to mix rather than to any softening in list pricing, noting that Marlboro's retail price was up roughly 7% year over year. The segment took list price increases of $0.20 per pack on Marlboro and L&M in both January and April, and $0.25 on other premium brands, so the price ladder itself did not change.

"What you've seen in terms of PM USA's price realization this quarter is actually the fact that you had strong Marlboro price realization, and that was somewhat offset by the mix related to Basic as Basic has grown volume and share." — Salvatore Mancuso, Chief Executive Officer

The revenue bridge supports the explanation without making it reassuring. Pricing contributed $309 million against $330 million in the first quarter, so gross price take was largely intact. Volume and cigarette mix took $279 million against $196 million. The realized rate fell because the denominator's composition changed, not because the price increases got smaller.

Assessment: The mechanism is exactly as described, and that is the problem rather than the reassurance. A blended realization rate that falls 180 basis points while list pricing holds is telling you the mix is migrating fast enough to overwhelm the pricing engine. Discount went from 5.5% to 9.6% of segment sticks in twelve months. If that migration continues at this pace, blended realization keeps falling toward the discount rate regardless of what PM USA does with the Marlboro price list, and the model that has funded Altria for two decades stops working at the reported level even while working perfectly at the brand level.

4. Marlboro Cowboy Cut and the Premium-Value Paradox

Cowboy Cut, introduced in the second quarter and tied to the country's 250th anniversary, is a Marlboro line extension aimed at value-sensitive premium smokers. Management described it as an instrument of revenue growth management rather than a new brand, and declined to give a share trajectory or a sourcing breakdown. One analyst noted that at retail in the markets observed it appeared to carry roughly a 40% discount to mainline Marlboro.

"You should think of Cowboy Cut as one of the many tools in the suite of RGM tools that PM USA uses to engage with consumers." — Salvatore Mancuso, Chief Executive Officer

Management's framing throughout was that the objective is to keep pressured consumers inside the Marlboro franchise rather than to let them leave for discount brands, and that the targeting is store-level and data-driven in the same way Basic's repositioning has been.

Assessment: Retaining a smoker inside Marlboro at a heavy discount is better than losing them to a competitor's discount brand, and worse than the price realization Altria was earning from them last year. Cowboy Cut is the premium-segment analogue of Basic, and it will show up in the same place: in a blended realization rate that keeps falling while brand-level pricing looks fine. Management is treating both as pure share-defence wins. The company's own operating income bridge is charging $221 million a quarter for the privilege, and the disclosure does not separate how much of that is Basic and how much is now Cowboy Cut.

5. Basic Meets Its Comparison

Basic's targeted promotional footprint reached roughly 35,000 stores in the first half, and its retail share grew 2.3 points year over year and 0.3 points sequentially. Management was explicit that the sequential increment is flattening and that the second half laps the original repositioning. Asked whether cigarette volumes should therefore be worse in the second half, the answer separated Altria's strategy from the category's direction: participation in discount, not acceleration of it.

"And then, yes, Basic has shown strong growth on a year-over-year basis, and we will start to lap that. But we -- again, our strategy in discount is to participate in discount and not necessarily accelerate the growth in the discount category you're seeing. And that growth in the category is really driven by consumers' decisions to trade-down during a difficult economic situation." — Salvatore Mancuso, Chief Executive Officer

Assessment: This confirms what the April call implied: the discount share gain is close to its natural ceiling under the current framework. That has two consequences the market has not obviously priced. Total PM USA category share, which grew 30 basis points this quarter almost entirely on discount, loses its engine when the comparison laps. And the mix headwind to price realization becomes an annualized level rather than a widening drag, which is arithmetically better for 2027 than for the second half of 2026. Modelling the share line off the last two quarters overstates the second half.

6. on! PLUS Finally Moves the Share Line

on! PLUS reached approximately 120,000 stores, covering about 90% of nicotine pouch category volume, up from roughly 100,000 stores and 85% of category volume at the end of the first quarter. The retail trade programme secured premium visibility across stores representing about 90% of Helix volume. Against that distribution base, on! took 0.8 points of sequential share in total oral tobacco and 1.0 point of sequential share in the pouch category.

"Share was up 0.8 share points sequentially. That is driven by the on! PLUS launch. The consumer likes the differentiated experience of the soft pouch technology. But we also recognize it's important to have higher strengths." — Salvatore Mancuso, Chief Executive Officer

Management characterized the consumer response as incremental to the on! portfolio, sourcing from both existing on! consumers and competitive pouch consumers, and said early repeat purchase rates were encouraging. It also stated it is agnostic to cannibalization of on! classic provided the consumer stays inside the on! family. As in April, no offtake figure, no repeat rate and no target share level were given.

Assessment: This is the first evidence in the covered window that distribution is converting into consumer pull rather than pipeline. A point of sequential pouch-category share is not a trend, but it is the specific measurement we said in April would determine whether the smoke-free half of the thesis is working, and it moved the right way faster than the first quarter suggested it would. The reservation is unchanged in kind: management is still describing the input in units of stores and shelf space and refusing to publish the output. "Encouraging repeat purchase rates" without a rate is the same disclosure posture that made the April launch impossible to underwrite.

7. The 12-Milligram Restart and the Flavour Pipeline

Helix resumed shipments of 12-milligram on! PLUS in Mint, Wintergreen and Tobacco in Florida, North Carolina and Texas during the quarter, with national expansion planned for the third quarter. Flavour extensions across 6-, 9- and 12-milligram strengths begin with Blueberry Mint and Mango Pineapple in the fourth quarter. Management repeated that higher nicotine strengths and broader flavours are where the category competes and acknowledged that on!'s current portfolio is concentrated in Mint and Wintergreen.

"We understand that flavors are important to this category. And while the larger flavor portfolio is in Mint and Wintergreen, other flavors are important. So we're excited about our ability to launch that later in the year in the fourth quarter." — Salvatore Mancuso, Chief Executive Officer

Assessment: The two weaknesses identified in April, strength and flavour breadth, both now have dated remedies, which is more than the April call offered. Both also land in the second half, which means the share inflection recorded this quarter was achieved without them. That is the encouraging reading. The cautious one is that the fourth-quarter flavour launches carry launch spending into a period whose earnings guidance is already the tighter half of the range, and management confirmed on the call that this expansion "will require a level of investment."

8. The FDA Enforcement-Priority Update

The FDA updated its enforcement priorities for certain e-vapor and nicotine pouch products during the quarter. Management read it as a distinction between products in advanced stages of review and products evading oversight entirely, and as creating a potential accelerated supplemental pathway for on! PLUS line extensions given the authorizations Helix already holds. It was careful to say the guidance does not substitute for formal authorization.

"While the guidance does not replace the need for formal authorizations, it recognizes that products in advanced stages of FDA review should be treated differently from products that evade regulatory oversight entirely." — Salvatore Mancuso, Chief Executive Officer

Management also laid out the review clock mechanics for the first time: for a supplemental application the clock begins on FDA acceptance, and for a full premarket tobacco product application the six-month period begins when it enters scientific review.

Assessment: This is the most consequential regulatory development of the quarter and it is not in the numbers. In April, the six additional flavour applications sat outside the pilot programme, which we flagged as removing the streamlined path from exactly the varieties management says decide the category. The updated enforcement priorities plus the existing on! PLUS authorizations restore some of that optionality. It is a clarity improvement rather than an authorization, and it does not change 2026 economics, but it materially improves the odds on the 2027 flavour portfolio.

9. NJOY ACE: The Patent Obstacle Clears, the Date Does Not

The most substantive new disclosure of the call was that NJOY has modified the ACE products so that they no longer infringe the four patents underlying the International Trade Commission exclusion order, that Customs and Border Protection concurs with that assessment, and that a supplemental premarket application has been submitted. Management confirmed the intent to re-enter and declined to name a date, and full-year guidance continues to assume no 2026 return.

"If you remember, NJOY ACE was out of the market related to 4 patents that were filed in the ITC. We have modified those products. They no longer infringe on those patents, and Customs and Border Patrol agree with that perspective. So we have submitted a supplemental PMTA. Our plan is to re-enter the market at some point with NJOY ACE." — Salvatore Mancuso, Chief Executive Officer

Pressed again later, management restated the position without moving it, tying re-entry to sustained enforcement against illicit manufacturers and continued FDA authorizations rather than to a calendar.

Assessment: In April the framing was significant progress on the patent dispute, offered with no specifics. This quarter the legal obstacle is described as resolved with a third-party agency concurring. That converts NJOY from a blocked asset into a timing decision, which is a genuine change in the option's character even though nothing in 2026 numbers moves. The tell is that management now attributes the delay to market conditions rather than to the litigation, which means the company has concluded the economics of re-entering into a category still dominated by illicit product do not work yet. That is the right commercial judgment and it postpones the only visible route back into the largest smoke-free pool in the country.

10. The USSTC Manufacturing Consolidation and the Capex Raise

Altria recorded $88 million of pre-tax asset impairment, exit and implementation charges in the quarter, $79 million of it in the oral segment, primarily for the consolidation of USSTC's manufacturing operations. Full-year capital expenditure guidance was raised to $375 million to $450 million from $300 million to $375 million, an increase of $75 million at both ends, primarily to fund the same programme. Neither the total programme cost nor a savings target nor a completion date was disclosed, and no analyst asked.

The consolidation is the reason reported oral operating income fell 23.5% against an adjusted decline of 8.0%, and it will keep the reported and adjusted oral margins roughly 1,150 basis points apart while the programme runs.

Assessment: Consolidating moist smokeless manufacturing capacity is the rational response to a base declining at a double-digit rate, and taking the charge now rather than defending stranded capacity is the right call. It is also an undisclosed programme of unknown size taking real cash out of a year in which free cash flow is the constraint on the buyback. A $75 million capex increase is not large against $8 billion of operating cash flow, but it is roughly 20% of the remaining share repurchase authorization, and the company has provided no framework for judging when the spending stops or what it returns.

11. Capital Returns Go Quiet

Altria repurchased 0.8 million shares for $55 million in the quarter at an average price of $65.11, against 4.5 million shares for $280 million in the first quarter. First-half repurchases were $335 million and $665 million remains under the $2 billion programme, which expires on 31 December 2026. Dividends of approximately $1.8 billion were paid in the quarter and $3,556 million in the half, up 3.0%, at an annualized rate of $4.24 per share against a progressive goal of mid-single-digit annual growth through 2028. Debt to consolidated EBITDA was 1.9x against a target of approximately 2x, and total debt fell to $24,577 million from $25,709 million at year end.

Capital allocation received no airtime in prepared remarks and surfaced only in the final question, on the 2026 and 2027 maturities. The framing offered was the standard hierarchy without a commitment.

"Historically, after we have the dividend, we have about $1 billion excess in cash. And we look at capital-efficient ways to deploy that capital, one in which you're pointing to is our debt management. And we also look at other capital-efficient ways like share buyback." — Heather Newman, Chief Financial Officer

Assessment: The dividend is intact, covered and unthreatened, and it is 95% of what shareholders receive. The buyback is a different matter. Repurchasing $55 million at an average price of $65.11, having spent $280 million at $62.33 in the prior quarter, is either a deliberate liquidity choice around the April settlement payment or a signal that the second-half free cash flow does not support the pace. Management did not say which. At the current run rate the remaining $665 million expires unused, and nothing on the call addressed whether the programme gets refreshed.

12. Cash Flow Inflects the Other Way

Second-quarter operating cash flow of $719 million compares with $205 million a year ago, and free cash flow of $662 million with $173 million. The first half produced $3,043 million of operating cash flow against $2,925 million and $2,893 million of free cash flow against $2,855 million, growth of 1.3%. The driver is not operating: Altria paid approximately $2.6 billion under the state settlement agreements and FDA user fees in the half, against $2.9 billion a year earlier, with substantially all of it in the second quarter of each period.

Assessment: Our April note predicted a sharply negative second-quarter free cash flow print on the April settlement payment. That was wrong, by roughly $700 million, because the payment itself came down $0.3 billion and because working capital moved favourably. The correction matters in both directions: the quarter is better than we expected, and the reason is a smaller settlement charge rather than better cash conversion. First-half free cash flow growth of 1.3% against first-half adjusted earnings growth of 4.9% is the honest measure, and cash has now grown slower than adjusted earnings in the first quarter and across the half alike. The standalone second quarter is the exception, and it is an exception created by a smaller settlement payment rather than by conversion.

Guidance & Outlook

The narrow was presented as a vote of confidence and priced as the opposite. Management raised the floor by $0.05 on the strength of a first half that grew 4.9%, and left the ceiling exactly where it was in January. The arithmetic that followed is what the market reacted to: a midpoint of $5.665 against a Street that was already carrying $5.69. A company that beats and narrows normally drags consensus up. This one narrowed to a level consensus had to come down to meet.

"We are raising the lower end of our full year 2026 guidance. We now expect to deliver adjusted diluted EPS in a range of $5.61 to $5.72, representing a growth rate of 3.5% to 5.5% from a base of $5.42 in 2025." — Heather Newman, Chief Financial Officer

Management named three things it is watching into the second half: the financial health of a consumer facing elevated gas prices and persistent inflation, the investment required behind the national 12-milligram launch and the fourth-quarter flavour extensions, and the timing of the export-related tax refunds. Only the third is arithmetic; the first two are spending decisions the company controls.

"As you go into the second half of the year, I think it's important to keep an eye on the financial health of the consumer. The consumer remains under pressure. Gas prices and inflation remain elevated, driven primarily by the uncertainty and the geopolitical climate that they are living in today." — Salvatore Mancuso, Chief Executive Officer

Implied second-half ramp: First-half adjusted diluted EPS of $2.80 leaves $2.81 to $2.92 for the second half against $2.75 in the corresponding 2025 period, which is 2.2% to 6.2% growth with a midpoint of 4.2%. The first half grew 4.9%. At the floor, the implied second-half growth rate is less than half what the first half delivered, and the second half must absorb the on! PLUS national strength launch, the fourth-quarter flavour extensions and the lapping of Basic's repositioning. It must also collect a duty-drawback benefit larger than the first half's, from a mechanism that just failed to grow sequentially.

Street at: Consensus entering the print sat at approximately $5.69, roughly $0.025 above the new midpoint and $0.03 below the ceiling. The narrow therefore does not validate the Street number; it brackets it in the upper half of the range and requires the second half to run above the midpoint for consensus to be met. That is a subtly different setup from April, when reaffirming a wider range left the beat as buffer.

Guidance style: Altria set its band in January, reaffirmed it through the first quarter and has now narrowed it at mid-year. What is unusual is narrowing to a midpoint below where the Street sits after a first half that beat. The most defensible reading is that management is protecting against a second half in which the consumer deteriorates and the launch spending lands as planned, and is willing to let the Street come down rather than commit to the upper half. Altria has historically landed inside its band rather than above it, which makes the ceiling the less relevant end of the range.

Analyst Q&A Highlights

Why the Second Half Looks Flat Against the First

The opening question of the call went directly to the shape of the year, pairing the raised floor against a first half that had already delivered $2.80 and asking what the second half absorbs. The answer named consumer health first and launch investment second, and confirmed that the year has phased differently from the January plan. It did not dispute the premise that the implied second-half growth rate is the slower one.

Q: "You raised the low end of the guidance range. But even with that, the low end is below the first half delivery. And I think initially, you anticipated a stronger phasing of growth in the second half. So how should we think about the second half now given some commentary around building benefits from the duty drawback? Are you stepping up investments? You talked about some launches behind on! PLUS and you have Cowboy Cut going into the market. So are you stepping up incremental investments? Or are there other considerations in the second half we should think about?"
— Matthew Smith, Stifel

A: "Look, we were really pleased that we could narrow guidance for our investors coming out of the second quarter. Really pleased with the first half results, to your point. And yes, the timing played out somewhat differently than our -- what we thought at the very beginning of the year. As you go into the second half of the year, I think it's important to keep an eye on the financial health of the consumer."
— Salvatore Mancuso, Chief Executive Officer

Assessment: The admission that "the timing played out somewhat differently" than the January plan is the most candid line on the call, and it is doing more work than it appears. In April the phasing was revised from second-half weighted to balanced on the strength of first-quarter volume. Three months later the second half is again the harder half, and the reason offered is spending the company chose to schedule there. Confirming the investment step-up rather than deflecting it was the right answer, and it is also the reason the ceiling did not move.

Why the Export Refund Did Not Follow the Export Volume

The most technically precise question of the call isolated the fact that export volume rose sequentially while the associated refund did not, and asked whether that indicated a problem with the import leg or merely a timing artefact. The response confirmed the latter and named the two mechanics, the lag on filing the credit claim and the staging of inventory. It did not size any of it, and the absolute benefit remains undisclosed for a third consecutive quarter.

Q: "I had a question on the double duty drawback. I guess I'm hoping for a little bit more color on why you didn't recognize more of a benefit in Q2. You did export more volume sequentially. So I guess I assume something happened with the import volume quantity. I'm asking because I just want to make sure there's, I don't know, no issue and you have good visibility on this really ramping in 2H versus 1H."
— Bonnie Herzog, Goldman Sachs

A: "For double duty drawback, you're absolutely right to point out export volumes increased Q1 to Q2. Really, what you're seeing is a timing factor. And so there are 2 components to that, why that's not truing up to the FET credit. One is the time in terms of when we apply for that credit. The other is just staging of products, some inventory movement, and that's why that's not perfectly lining up."
— Heather Newman, Chief Financial Officer

Assessment: A direct, mechanically credible answer to a question management should have pre-empted in the prepared remarks. The disclosure gap is the issue rather than the explanation. An investor working only from the release and the call cannot size an item that has now contributed roughly a third of segment operating income growth in each of two consecutive quarters, and the second-half guide depends on that item growing. The company continues to disclose the year-over-year increment only in the Form 10-Q and never the absolute.

Whether the Volume Moderation Survives the Second-Half Comparisons

A recurring line of questioning tested whether the improving volume trend is durable or an artefact of easy comparisons, and pressed specifically on whether Basic's lapping means reported volumes deteriorate in the second half. The answer decomposed industry decline into secular, elasticity and cross-category components, attributed the moderation to enforcement and to saturation of the pool willing to convert, and conceded the first-half comparison benefit without forecasting the second half.

Q: "As you guys have highlighted, cig volume declines are moderating. So just maybe hoping for a little bit more color on what you think might be driving this and whether you expect this to continue? And then I'm also asking in the context of sort of something you just touched on, Heather, is Basic because as I think about the second half, you're going to have pretty tough comps for Basics. So just trying to understand if we should realistically assume your cig volumes will be worse in 2H versus 1H."
— Bonnie Herzog, Goldman Sachs

A: "One is the elevated level of enforcement that we're seeing in the marketplace and some of the supply-chain disruption that is occurring related to the illicit disposable e-vapor products. And then these products have been available for a number of years and the consumers, many of them had moved already into these categories. So we think both are probably playing a role in the moderation of the decline rate that you're seeing. And we'll have to see -- we don't talk about future volume trends necessarily, but we'll have to see how innovation impacts cross-category movement going forward."
— Salvatore Mancuso, Chief Executive Officer

Assessment: The two-mechanism explanation is unchanged from April and remains the strongest argument in the equity, but the caveat management appended is new and important. "We'll have to see how innovation impacts cross-category movement going forward" concedes that the saturation argument holds only until the next product format arrives. That is a materially more honest framing than the April call's, and it is the reason we still decline to capitalize the improvement into a permanently lower terminal decline rate.

Whether the Reported Volume Outperformance Unwinds

A question on price elasticity and inventory carried the sharpest modelling observation of the call: that reported shipments have been running roughly 120 to 130 basis points ahead of the inventory-adjusted figure, and that the gap should reverse. Management confirmed the elasticity coefficient is unchanged, restated that premium carries roughly 85% of category profitability, and attributed the outperformance to the portfolio strategy rather than addressing the inventory unwind directly.

Q: "U.S. industry volumes, following up from the previous question, clearly better so far this year. Just wanted to check, are you seeing any impact from higher gas prices because even Q2 volumes were strong? Or is there a change in that correlation? And in terms of your shipments, your shipments are almost 120, 130 basis points better than the inventory adjusted number. So should we expect that to unwind in the second half?"
— Pallav Mittal, Barclays

A: "And we are seeing change to the price elasticity seen for a period of time, that coefficient of negative 0.35% continues to hold steady. You do see, obviously, as I pointed out in Bonnie's question, the growth of the discount category in the cigarette space, and that's consumers making trade-down decisions. But premium remains the category or the segment where most of the profitability is in the cigarette category, it's about 85% of the profitability in the cigarette category."
— Salvatore Mancuso, Chief Executive Officer

Assessment: The question was answered on elasticity and left unanswered on inventory. That matters because the same gap flattered the first quarter, where reported was 2.4% against 4% adjusted, and it flattered this one, 3.2% against 4.5%. Two consecutive quarters of building trade inventory is a reported-volume tailwind that has to reverse. The elasticity disclosure is the more useful half of the answer: an unchanged coefficient of negative 0.35 means the trade-down is being driven by consumer income, not by Altria's price ladder, which is the better of the two explanations for the mix shift.

Why Pouch Volumes Lagged the Distribution Gains

The oral franchise drew the most persistent questioning of the call, focused on the disconnect between national distribution and a shipment line that fell 4.2%. Management separated the two, attributing the volume figure to a promotionally inflated prior-year quarter and to first-quarter pipeline timing, and pointing to the sequential share gain as the cleaner read on consumer response.

Q: "Can you just talk about the consumer feedback on the on! PLUS product, the recent 12 mg launch and any retention rates since you have gone national in March? The reason I asked this question is because despite the national expansion, volumes haven't accelerated significantly. So just wanted to check if there is any inventory movement which is impacting the Q2 numbers? Or is there something more than that?"
— Pallav Mittal, Barclays

A: "You are right, when you talk about shipments, there were some comp issues related to the second quarter. So if you look at 2025, volume was up due to some promotional activity as a major competitor was having some supply-chain disruption, it was important for Helix to promote the on! product. And then you have some timing between first quarter and second quarter as on! PLUS national launch was being prepared."
— Salvatore Mancuso, Chief Executive Officer

Assessment: Both explanations check out against the disclosure. Inventory-adjusted segment volume fell 2% against a reported 8.5%, which supports the timing argument, and the prior-year quarter is identifiable as unusual. The retention question was again not answered with a number, for the second consecutive quarter, which is now a pattern rather than a function of the launch being early. Share is the output that matters and it moved; the company should be willing to publish the repeat rate that it says is encouraging.

Where on! PLUS Volume Is Being Sourced From

A follow-up asked how much of the new product's volume is incremental to the pouch category and where the rest is coming from. The answer claimed sourcing from three pools, existing on! consumers, competitive pouch consumers and moist smokeless consumers, and stated explicitly that the company is indifferent to cannibalizing its own classic product provided the consumer stays inside the franchise.

Q: "In terms of on! PLUS any insights as to what you're seeing in terms of consumer sourcing? How much of it is kind of incremental to the category? And of the part that's not incremental, where do you see it sourcing the most volumes from -- either from a segment and strength or a brand standpoint?"
— Eric Serotta, Morgan Stanley

A: "And I have to tell you, we're agnostic that it may source some from on! classic if they stay within the on! family. And on! PLUS, we believe, is a differentiated product related to the NICOSILK soft pouch technology. And we believe over the long term, it will be a premium product because of its differentiation."
— Salvatore Mancuso, Chief Executive Officer

Assessment: Indifference to internal cannibalization is the correct posture when the alternative is losing the consumer to a competitor, and the claim that on! PLUS also pulls from moist smokeless is the more interesting half. If true, the product is accelerating the very mix migration that is compressing segment margin, converting a high-margin moist smokeless can into a lower-margin pouch can inside Altria's own portfolio. That is still better than losing the consumer entirely, and it means the segment's margin decline should be read as partly self-inflicted and partly permanent.

What the Price/Mix Deceleration Actually Signals

The most analytically pointed question of the call observed that price/mix decelerated by roughly two percentage points while Basic's year-over-year share expansion was no larger than in the first quarter, and asked what else changed. The answer confirmed that the deceleration is mix rather than list price, and supplied the one hard datapoint that separates the two: Marlboro's retail price was up about 7% year over year.

Q: "If my math is right, I think there's at least a couple of percentage points of deceleration in price/mix at a time when the Basics share expansion year-on-year is sort of no different compared to Q1. Could you just help me understand what maybe drove the incremental step down in price/mix, whether that's related to Marlboro pricing or the impact of Cowboy Cut?"
— Mirza Faham Baig, UBS

A: "So just to give you some point of reference, if you look at Marlboro retail price in the second quarter, it was up about 7% on a year-over-year basis. We do believe that the recent guidance from FDA is constructive. While it doesn't replace the importance of authorization, we do believe that it brings some clarity and transparency related to authorization, both in the nicotine pouch as well as the e-vapor category."
— Salvatore Mancuso, Chief Executive Officer

Assessment: The 7% Marlboro retail price figure is the most useful number management volunteered all call, because it isolates the deceleration as entirely compositional. Brand-level pricing power is not eroding. What is happening is that the mix is moving toward products where that power does not apply, and it is moving fast enough to cut blended realization by 180 basis points in a single quarter. The question's implication, that Cowboy Cut may be contributing alongside Basic, was not addressed, and the company does not disclose enough to separate them.

What They're NOT Saying

1. The absolute size of the duty drawback, for a third quarter: Only the year-over-year increment is disclosed, and only in the Form 10-Q. Management confirmed the benefit was "flat sequentially" without ever attaching a dollar to either quarter. The second-half guide depends on this item growing, and no investor can size the base it grows from.
2. Why the buyback fell 80%: Repurchases dropped to $55 million from $280 million with no explanation offered and none requested. $665 million of authorization expires on 31 December 2026. Whether the programme gets refreshed, and whether the deceleration reflects the April settlement payment or a view on second-half free cash flow, was not addressed in prepared remarks or in Q&A.
3. The scope of the USSTC manufacturing consolidation: $88 million of charges in the quarter, $79 million of it in the oral segment, and a $75 million increase to the capital expenditure range, for a programme with no disclosed total cost, no savings target and no completion date. It received no analyst question at all.
4. on! PLUS consumer offtake and repeat rates: Second consecutive quarter of "encouraging repeat purchase rates" and "early data suggests" with no rate, no offtake figure and no target share level. The share line moved this quarter, which makes the continued refusal to publish the underlying consumer metrics less defensible, not more.
5. Copenhagen: The brand lost 2.8 points of oral category share and shipped 10.9% fewer cans, and was characterized on the call only through the phrase "resiliency of our MST brands" and a reference to maintaining premium leadership. Moist smokeless is where the segment's margin lives; its decline received less airtime than the retail trade programme.
6. Any volume guidance: Now four consecutive quarters of describing moderation without committing to a decline rate, and management restated on this call that it does not discuss future volume trends. The single most important variable in the equity remains entirely an analyst judgment.
7. Whether the reported-versus-adjusted volume gap reverses: Asked directly whether the 120 to 130 basis point cushion unwinds in the second half, management answered on elasticity and portfolio strategy and never returned to the inventory question.
8. How much of the mix drag is Cowboy Cut: The $221 million volume and cigarette mix charge is disclosed as a single figure. With a premium line extension now discounting alongside a growing discount brand, the company gives no way to separate a deliberate premium price concession from consumer-driven trade-down.

Market Reaction

• Pre-print setup: Closed at $74.92 on 29 July, up 29.9% year to date against 6.9% for the S&P 500, up 21.8% over the trailing twelve months and 4.1% over the trailing thirty days. That close was the top of the 52-week closing range of $54.72 to $74.92, so the stock entered the print at its highest close of the past year.
• Reaction session (30 July, before-open print): Opened at $70.69, down 5.6%, which was also the session high; traded as low as $67.63, down 9.7%; closed at $67.94, down 9.3% or $6.98. The open was the high and the close was within thirty-one cents of the low.
• Volume: 21.3 million shares against a 7.8 million thirty-day average, 2.7 times normal.
• Relative: The S&P 500 rose 1.7% on the session, so the stock underperformed the index by 11.0 points in a day and gave up roughly $11.7 billion of market value on the quarter's 1,670 million weighted-average diluted shares.
• Peer reaction: The whole complex fell. Philip Morris International declined 3.2%, British American Tobacco 2.2% and Turning Point Brands 0.5%, while the consumer staples sector fund fell 2.2%.

This was the mirror image of April, and the symmetry is instructive. In April a single company's print pulled three other tobacco names up on a day the index rose 1.0%, because the market extracted an industry datapoint about terminal decline from a company release. This time the complex fell together on a day the index rose 1.7%, which says the market again read the print as sector information. The difference is what the information was about. In April it was volume; this time it was the profit that volume converts into.

The idiosyncratic portion is roughly six points beyond the next-weakest large-cap peer, and it is attributable to three specific things in the release rather than to the two-cent miss. The guidance narrow put the midpoint below where consensus sat, so the beat-and-narrow that normally lifts estimates instead required them to come down. The capital expenditure range went up $75 million for a programme nobody has sized. And the segment that was supposed to be improving produced 38% of its operating income growth from a tax refund that failed to grow.

The intraday shape supports that reading. A stock that gaps down 5.6% on the print and then loses another 3.7 points across the session is not reacting to a headline; it is reacting to a document. The pre-market decline was reported at 7.7%, the open was 5.6% lower, and the close was 9.3% lower. Selling accelerated as the release was worked through, which is the pattern of a market discovering the composition of the quarter rather than its headline.

The setup did most of the damage. A stock up 29.9% year to date against 6.9% for the index, closing at a 52-week high the day before a print, carries no cushion for a quarter that is merely adequate. Altria delivered adequate. At $67.94 the shares have given back most of the April re-rating: the forward multiple on the new guidance midpoint is 12.0 times against 13.2 times the day before the print, and the yield is 6.24% against 5.66%. That is below where we initiated coverage in April, at $72.65 and 12.9 times.

Street Perspective

Debate: Is the Volume Moderation Now a Trend?

Bull view: Four consecutive quarters of moderated industry declines, two of them with Altria's inventory-adjusted rate inside 4% to 5% against an industry 5%, is no longer a datapoint. The enforcement evidence base widened this quarter to named seizures, a state attorney general action and payment-platform restrictions, and the adult vaper population has been flat for twelve months on two separate readings. If the terminal decline rate for US cigarettes is 4.5% rather than 8%, the sector's discounted cash flow models are wrong by a wide margin and this is the purest expression of the correction.

Bear view: Reported volume has run 120 to 130 basis points ahead of the inventory-adjusted figure for two consecutive quarters, which is a cushion that must reverse. The first half also lapped an unusually weak prior-year period, which management conceded. And the volume that is holding is discount volume: 9.6% of segment sticks against 5.5%, growing 67%, at a fraction of premium economics. Stabilizing units while degrading mix is not the same thing as stabilizing the business.

Our take: The bulls have won the volume argument and the bears have won the profit argument, which is a different split from April. We now accept the moderation as real: two quarters at 4.5% and 4.0% inventory-adjusted, with the industry at 5% both times and a broader evidence base for enforcement, is enough to stop treating it as noise. What we will not do is capitalize it, because management itself flagged that the saturation case holds only until the next product format arrives, and because the mix degradation is currently consuming the benefit faster than the volume improvement is creating it. Volume is no longer the swing variable in this equity. Mix is.

Debate: Does the on! Share Inflection Fix the Smoke-Free Case?

Bull view: The specific measurement that the bear case has rested on for a year finally turned. on!'s share of the nicotine pouch category rose 1.0 point sequentially to 14.4% and its total oral share rose 0.3 points year over year, the first year-over-year gain since we began covering the name. That happened before the national 12-milligram launch and before the fourth-quarter flavour extensions, which are the two remedies to the portfolio's known weaknesses. Distribution is now at 120,000 stores and 90% of category volume, and the FDA's enforcement-priority update improves the odds on the next round of authorizations.

Bear view: One point of sequential share in the quarter immediately following a national launch is what launch mechanics produce, and the year-over-year comparison is still negative by 1.7 points. Meanwhile the segment's economics went the wrong way: adjusted operating income fell 8.0%, margin fell 200 basis points, and Copenhagen shed another 2.8 points of category share while shipping 10.9% fewer cans. Altria is trading a high-margin moist smokeless can for a low-margin pouch can, by management's own account partly inside its own portfolio, and the Master Settlement Agreement still bars Copenhagen and Skoal from the format.

Our take: This is the most improved element of the thesis and the one we were most wrong about the pace of. In April we wrote that until on!'s pouch-category share stops falling, the smoke-free half of the case is not working. It stopped falling in the very next quarter, with both the numerator and the denominator moving favourably, and the internal consistency of the two disclosed share measures makes the result hard to dismiss as a survey artefact. We are moving this from a materializing risk to an emerging one. But the segment is now shrinking in dollars while gaining in pouches, and that is the shape of a mix migration into a thinner category rather than a return to growth. The share fix improves the terminal-value case; it does not improve the earnings case, and it will not until pouch volume can carry the segment alone.

Debate: Is 12.0x With a 6.2% Yield the Bottom of the De-Rating or the Start of One?

Bull view: The stock has given back the entire April re-rating and more, on a quarter that missed by two cents and raised the low end of guidance. At 12.0 times the guidance midpoint with a 6.24% yield, a progressive dividend commitment through 2028, leverage at 1.9 times against a 2.0 target and a business whose volume decline rate has halved, the risk/reward is better than it was at $72.65 in April by every measure that matters. A 9.3% session on a two-cent miss is positioning unwinding, not thesis breaking.

Bear view: The multiple compressed because the earnings quality justified it. Half of this quarter's adjusted growth came from buyback and tax rate, and the buyback just fell 80% with $665 million of authorization expiring in December. A third of segment operating income growth came from a tax refund that failed to grow and that the second-half guide requires to grow. The tax rate is already at 23.0%. Strip the three below-the-line and non-operating contributors and this business grew approximately nothing, and it is being asked to fund a dividend, a manufacturing consolidation and two product launches simultaneously.

Our take: The bears are right about the quarter and the bulls are right about the price, which is why the rating does not change. In April we called the multiple the reason to stay out; that objection is now largely resolved, and a 6.24% yield at 12.0 times is a defensible entry for an income mandate. What replaced it is a genuine deterioration in the composition of the earnings, arriving in the same quarter that the two structural bear points improved. Those cancel. The forward total return from here is the 6.24% yield plus low-single-digit growth, call it 9%, against a market-like alternative. That is not a bargain and it is no longer expensive.

Model Update

Valuation framework: Applying 11.5 to 12.5 times to a FY2027 adjusted diluted EPS estimate of roughly $5.85 produces a fair-value range of approximately $67 to $73 with a midpoint near $70. The multiple range is narrower and one half-turn lower than April's 12.0 to 13.0 times, because the quarter demonstrated that a materially larger share of the earnings is coming from below the operating line and from a tax refund whose timing the company does not control. Against the $67.94 close that implies roughly 3.0% of price return, plus a 6.24% dividend yield, for a total return near 9% over twelve months.

What would change the rating. A third consecutive quarter at an inventory-adjusted 4% to 5% decline, with the discount mix charge against segment operating income flattening rather than widening from the $221 million printed here, would complete the upgrade case that this quarter half-satisfied. So would a second consecutive quarter of sequential pouch-category share gains alongside a return to oral segment operating income growth. On the other side, a duty-drawback benefit that fails to step up again in the third quarter would put the guidance floor at risk and take us to Underperform, as would blended price realization falling below roughly 3.5%, which would mean the mix migration has outrun the pricing engine.

Thesis Scorecard Post-Earnings

The table grades the seven pillars established at initiation in April against what this quarter's print and call revealed. The wording is carried forward as written, except that Bull 3 no longer quotes April's 5.8% yield, which the sell-off has superseded.

Grading Our April Checkpoints

Overall: Thesis unchanged in direction and materially rebalanced in composition. The two structural bear points that made this a Hold at $72.65 both improved, one substantially: the pouch franchise took its first share gain and the multiple gave back the entire April re-rating. Against that, the pricing pillar moved to at risk and the earnings-quality point moved to materializing, because half of this quarter's growth came from below the operating line and a third of the segment's operating growth came from a tax refund that failed to grow. Two bull pillars now carry a flag, two bear points improved and two hardened. The net is a business whose volume problem is genuinely better and whose profit problem is genuinely worse, at a price that no longer assumes only the first.

Action: Hold. The April objection was price and it has been answered; a 6.24% yield at 12.0 times the guidance midpoint is a defensible entry for an income mandate, and we would no longer discourage initiating here. What stops us upgrading is that the quarter which delivered the valuation reset also delivered the thinnest operating contribution in the covered window, and the second-half guide leans on a duty-drawback ramp that has just missed once. We upgrade on a third consecutive quarter inside the 4% to 5% inventory-adjusted band with the mix charge flattening, or on a second sequential pouch-share gain alongside a return to oral operating income growth. We downgrade if the drawback misses again in the third quarter, which would put the guidance floor in play.

Bottom Line

Altria lost 9.3% and roughly $11.7 billion of market value on a two-cent miss, and the two-cent miss was not the reason. The reason is that a company which beat and narrowed put its midpoint below where the Street already sat, raised capital spending for a programme it has not scoped, cut its buyback by 80% without comment, and produced half of its earnings growth from share count and a tax rate. Underneath all of that, the parts of the business the thesis actually turns on got better: the cigarette decline held inside 4% to 5% for a second quarter against an industry 5%, and on! took its first sequential gain in the nicotine pouch category since the launch, faster than April's data suggested it could. Both of those matter more over five years than anything on the guidance line. Neither of them was worth paying 13.2 times and a 5.66% yield for, which is what the market was doing on 29 July. At $67.94, 12.0 times and 6.24%, the price has stopped assuming the good outcome and started assuming a fair one. We are maintaining Hold with fair value near $70, and for the first time we would not talk an income investor out of the entry.